Regulatory Update - Clarification on the FDA's Position on Compounding with Beta-Lactam Antibiotics

 

Regulatory Update – Clarification on the FDA’s Position on Compounding with Beta-Lactam Antibiotics

 

Why are compounders looking to compound amoxicillin?

Amoxicillin (a beta-lactam antibiotic) for oral suspension is currently on acute shortage. A comprehensive list of products on shortage can be found at the FDA’s site here: FDA Drug Shortages.

 

Why the specific concern regarding beta-lactam antibiotics?

Beta-lactam antibiotics are considered to represent a significant allergenic risk and cross-contamination between beta-lactam antibiotics and other drugs could potentially result in life-threatening allergenic reactions. The FDA has previously stated on their Insanitary Conditions at Compounding Facilities guidance for industry (GFI) that the processing of beta-lactams without complete and comprehensive separation from non-beta-lactam products is considered to be insanitary.

 

May 503a compounding pharmacies compound amoxicillin oral suspension during the shortage?

The recent GFI from the FDA, Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food, Drug, and Cosmetic Act, clarifies that enforcement and regulatory actions will be prioritized if the below steps are not followed when working with beta-lactam antibiotics:

1. Use of FDA-approved beta-lactam tablets and capsules instead of bulk drug substances to compound the beta-lactam oral antibiotic suspension product

2. Temporal segregation of the compounding of these oral suspensions from non-beta-lactam products

3. Use of dedicated or disposable equipment, utensils, and personal protective equipment (e.g., gowns, gloves)

4. Segregation and storage in a separate area of any equipment, utensils, and personal protective equipment used in the compounding of these oral suspensions (e.g., glassware, mortar and pestle) from equipment, utensils, and personal protective equipment not used in beta-lactam compounding

5. Trituration of the FDA-approved product after wetting it with a quantity of the suspension vehicle sufficient to eliminate formation of product dust

6. Use of proper cleaning procedures after completing compounding, including use of peroxide or bleach solutions to deactivate the beta-lactam ring of any drug residue on surfaces. The use of strong oxidizers should be followed by neutralizers and volatile cleaning agents (e.g., purified water, isopropanol) to minimize damage to these surfaces

7. Containment and remediation of spills

8. The beyond-use-date assigned to the compounded oral suspension does not exceed the beyond-use-date of the related reconstituted FDA-approved beta-lactam antibiotic powder for oral suspension product that is on FDA’s drug shortage list, as found on the approved labeling; and

 9. Storage conditions used for the compounded oral suspension are consistent with those for the related reconstituted FDA-approved beta-lactam antibiotic powder for oral suspension product that is on FDA’s drug shortage list, as found on the approved labeling.

 

For more information, read the complete GFI here: Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act | FDA

 

Sources:

Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food, Drug, and Cosmetic Act Immediately in Effect Guidance for Industry. U.S. Food and Drug Administration. November 18, 2022. Accessed November 18, 2022. Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act | FDA

Comments

Post a Comment

Popular posts from this blog

Guidance for Industry 256: Understanding Impacts on the Compounding Industry

  Guidance for Industry 256: Understanding Impacts on the Compounding Industry By Sarah Taylor, PharmD What is Guidance for Industry (GFI) 256? GFI 256 is a guidance for industry intended to provide clarification from the FDA on compounding animal drugs from bulk drug substances. The guidance does not apply to animal drugs compounded from FDA-approved animal or human drugs, which the FDA generally considers to be legal extra label uses of such drugs. 1 The FDA considers compounding animal drugs from bulk substances by pharmacists and veterinarians to violate aspects of the FD&C Act. Given the wide range of animal species and their varying needs, the FDA acknowledges that in some circumstances there may be no medically appropriate commercially available treatment options or commercially available FDA approved drugs may not be suitable for use as a source of active pharmaceutical ingredient (API) in some circumstances. This guidance lays out the circumstances in which the FDA
Read more

Developing Standard Operating Procedures

Image
 Developing Standard Operating Procedures by Denise M. Frank, RPh, FACA, FAPC   Policies and Procedures are the written pharmacy documents that include the policy statement (a course or plan of action, a high-level principle of the pharmacy), and the procedures for complying or carrying out a task. These procedures are also referred to as Standard Operating Procedures, or SOPs. Why do we need Policies and Procedures, and Standard Operating Procedures (SOPs) for the pharmacy? Policies and procedures will provide for the consistent performance of activities. Personnel have a reference on how to handle situations and perform tasks – working as a team. The manual will very useful when training new employees with clear explanations, instructions, and expectations for specific tasks and for their position. Well-written SOPs also help protect a pharmacy from liability. The policies and procedures, when followed, ensure staff are compliant with regulations and standards and this protects
Read more

Water Activity: USP 795 Changes

  Water Activity: USP <795> Changes Sarah Taylor, PharmD Beyond-use dating in the newly proposed USP General Chapter <795> underwent significant changes, particularly to the recommended maximum beyond-use dates allowed for different types of formulations. One of the biggest changes is a new focus on microbial growth and preservative efficacy. The guidelines define aqueous preparations as those having a water activity (a w ) greater than or equal to 0.6, and only preparations with an a w less than 0.6 are considered anhydrous dosage forms. 1   What is water activity? Water activity is a measurement of the ratio of vapor pressure of the substance in question when at equilibrium with the surrounding air to the vapor pressure of distilled water under identical conditions. 2 So, for example, an a w of 0.6 means that the vapor pressure of the substance in question is 60% that of pure water. Water activity should not be mistaken for water content. Water content is a meas
Read more